###begin article-title 0
The SIRT1 Deacetylase Suppresses Intestinal Tumorigenesis and Colon Cancer Growth
###end article-title 0
###begin p 1
Conceived and designed the experiments: DS LG RF GB SM PO SO SL. Performed the experiments: Rd RF GB SM PO SO JC AB SL CF. Analyzed the data: DS LG WH RF GB SM SO CF. Contributed reagents/materials/analysis tools: DS LG WH Rd RF GB SM PO SL. Wrote the paper: DS LG WH RF GB SM.
###end p 1
###begin p 2
Current address: Magen Biosciences, Cambridge, Massachusetts, United States of America
###end p 2
###begin p 3
Current address: Genstruct Inc., Cambridge, Massachusetts, United States of America
###end p 3
###begin p 4
###xml 352 353 352 353 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1301 1308 1289 1296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 655 660 <span type="species:ncbi:10090">mouse</span>
###xml 1174 1179 <span type="species:ncbi:9606">human</span>
Numerous longevity genes have been discovered in model organisms and altering their function results in prolonged lifespan. In mammals, some have speculated that any health benefits derived from manipulating these same pathways might be offset by increased cancer risk on account of their propensity to boost cell survival. The Sir2/SIRT1 family of NAD+-dependent deacetylases is proposed to underlie the health benefits of calorie restriction (CR), a diet that broadly suppresses cancer in mammals. Here we show that CR induces a two-fold increase SIRT1 expression in the intestine of rodents and that ectopic induction of SIRT1 in a beta-catenin-driven mouse model of colon cancer significantly reduces tumor formation, proliferation, and animal morbidity in the absence of CR. We show that SIRT1 deacetylates beta-catenin and suppresses its ability to activate transcription and drive cell proliferation. Moreover, SIRT1 promotes cytoplasmic localization of the otherwise nuclear-localized oncogenic form of beta-catenin. Consistent with this, a significant inverse correlation was found between the presence of nuclear SIRT1 and the oncogenic form of beta-catenin in 81 human colon tumor specimens analyzed. Taken together, these observations show that SIRT1 suppresses intestinal tumor formation in vivo and raise the prospect that therapies targeting SIRT1 may be of clinical use in beta-catenin-driven malignancies.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 187 190 187 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Weindruch1">[1]</xref>
###xml 217 221 217 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIR2</italic>
###xml 276 279 276 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Sinclair1">[2]</xref>
###xml 281 284 281 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Guarente1">[3]</xref>
###xml 319 323 319 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIR2</italic>
###xml 500 503 500 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Yamamoto1">[4]</xref>
###xml 640 643 640 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Lim1">[5]</xref>
###xml 672 680 672 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 793 800 793 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 942 945 942 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Chen1">[6]</xref>
###xml 969 972 969 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Cohen1">[7]</xref>
###xml 974 977 974 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Dai1">[8]</xref>
###xml 979 982 979 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Ford1">[9]</xref>
###xml 984 988 984 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Motta1">[10]</xref>
###xml 1049 1053 1049 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Pruitt1">[11]</xref>
###xml 1120 1127 1120 1127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1175 1179 1175 1179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Yeung1">[12]</xref>
###xml 1203 1207 1203 1207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Fu1">[13]</xref>
###xml 1209 1213 1209 1213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Chua1">[14]</xref>
###xml 1282 1289 1282 1289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1492 1496 1492 1496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Saunders1">[15]</xref>
###xml 63 69 <span type="species:ncbi:9606">humans</span>
###xml 1416 1422 <span type="species:ncbi:9606">humans</span>
Cancer is the second leading cause of age-related mortality in humans. Calorie restriction extends lifespan in all organisms tested and in mammals exerts strong tumor suppressive effects [1]. In lower eukaryotes, the SIR2 gene is proposed to mediate the health benefits of CR [2], [3]. SIRT1, the mammalian ortholog of SIR2, is induced by CR in multiple tissues of mammals, and has been shown to ameliorate degenerative diseases associated with aging, such as neurodegeneration and metabolic decline [4]. While CR is known to inhibit both spontaneous and induced tumor formation, a role for SIRT1 in this process remains to be demonstrated [5]. There are conflicting data in vitro as to whether SIRT1 will be found to act as an oncogene or as a tumor suppressor but to date there have been no in vivo studies that address this question. On the one hand, SIRT1 is upregulated in tumors and cancer cells lacking the tumor suppressor gene, HIC1 [6], can inhibit apoptosis [7], [8], [9], [10] and down-regulates the expression of tumor suppressor genes [11], leading many to conclude that SIRT1 will prove to be an oncogene in vivo. On the other hand, SIRT1 can be pro-apoptotic [12] and anti-proliferative [13], [14], and consequently has been proposed to behave as a tumor suppressor in vivo. Moreover, some have argued that mammalian longevity genes that delay age-related atrophic diseases may conversely predispose humans to a higher incidence of cancer due to their anti-apoptotic function [15]. This study addresses this controversial question by testing the effects of SIRT1 on tumor formation and growth.
###end p 6
###begin p 7
###xml 47 52 47 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">min/+</sup>
###xml 315 319 315 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Mai1">[16]</xref>
###xml 328 333 328 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">min/+</sup>
###xml 431 435 431 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Su1">[17]</xref>
###xml 552 556 549 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Munemitsu1">[18]</xref>
###xml 558 562 555 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Rubinfeld1">[19]</xref>
###xml 170 176 <span type="species:ncbi:9606">humans</span>
###xml 334 339 <span type="species:ncbi:10090">mouse</span>
We chose to test the effect of SIRT1 in the APCmin/+ model of colon cancer for a variety of reasons: it physiologically recapitulates the early events of colon cancer in humans, the mechanism of tumorigenesis is well characterized, and CR has previously been shown to reduce the rate of tumorigenesis in this model [16]. The APCmin/+ mouse contains a germline mutation in the adenomatous polyposis coli (APC) tumor suppressor gene [17]. Somatic loss of the second allele leads to constitutive nuclear localization of beta-catenin and adenoma formation [18], [19].
###end p 7
###begin p 8
###xml 144 148 141 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Logan1">[20]</xref>
###xml 246 250 240 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Korinek1">[21]</xref>
###xml 252 256 246 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Morin1">[22]</xref>
###xml 654 658 648 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Brack1">[23]</xref>
###xml 660 664 654 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Liu1">[24]</xref>
beta-catenin is the central effector in the canonical Wnt signaling pathway that controls stem cell maintenance, development and carcinogenesis [20]. Constitutive activation of the beta-catenin pathway has been found in 90% of colorectal cancers [21], [22]. In addition, this pathway is aberrantly activated in many other cancers including prostate, breast, ovary and melanoma. Interestingly, two recent studies have shown that increased Wnt signaling is associated with accelerated aging, suggesting that an attenuation of Wnt signaling might underlie CR and be beneficial not only for treating cancer but for more broadly attenuating diseases of aging [23], [24].
###end p 8
###begin p 9
###xml 72 77 72 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">min/+</sup>
###xml 78 83 <span type="species:ncbi:10090">mouse</span>
We report here that SIRT1 suppresses intestinal tumorigenesis in the APCmin/+ mouse model and inhibits colon cancer growth. We provide substantial evidence that the anti-tumorigenic effects of SIRT1 depend on its deacetylase activity and are mediated through inhibition of beta-catenin. These findings identify a tumor suppressive function for SIRT1, provide mechanistic insight, and suggest a therapeutic role for SIRT1 deacetylase activators in colon cancer.
###end p 9
###begin title 10
Results
###end title 10
###begin p 11
###xml 240 246 228 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ad lib</italic>
###xml 261 268 249 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002020-g001">Fig. 1A</xref>
###xml 399 406 387 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002020-g001">Fig. 1B</xref>
###xml 450 455 438 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">min/+</sup>
###xml 507 511 495 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-elMarjou1">[25]</xref>
###xml 561 570 549 554 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;STOP</sup>
###xml 584 589 568 573 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">min/+</sup>
###xml 666 675 650 655 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;STOP</sup>
###xml 714 723 694 699 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;STOP</sup>
###xml 756 763 732 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002020-g001">Fig. 1E</xref>
###xml 820 827 796 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002020-g001">Fig. 1F</xref>
###xml 140 144 <span type="species:ncbi:10116">rats</span>
###xml 392 397 <span type="species:ncbi:10090">mouse</span>
###xml 415 430 <span type="species:ncbi:10090">transgenic mice</span>
###xml 456 460 <span type="species:ncbi:10090">mice</span>
###xml 539 554 <span type="species:ncbi:10090">transgenic mice</span>
###xml 724 728 <span type="species:ncbi:10090">mice</span>
Earlier studies have shown a dramatic tumor suppressive effect of CR but the molecular mechanism(s) are currently unknown. We observed that rats on a CR diet have approximately2-fold higher levels of SIRT1 in the gut epithelium relative to ad lib-fed controls (Fig. 1A). To test the effect of increasing SIRT1 expression in intestinal epithelial cells, we generated a floxed SIRT1 transgenic mouse (Fig. 1B). SIRT1 transgenic mice were crossed to APCmin/+ mice followed by breeding to the Villin-Cre strain [25]. Thus, we generated triple transgenic mice (SIRT1DeltaSTOP; Vil-Cre; APCmin/+) which overexpress SIRT1 specifically in the gut villi (referred to as SIRT1DeltaSTOP). The SIRT1 levels in the gut of SIRT1DeltaSTOP mice were approximately 7-fold (Fig. 1E) and the morphology of villi appeared otherwise normal (Fig. 1F).
###end p 11
###begin title 12
###xml 36 51 <span type="species:ncbi:10090">transgenic mice</span>
Generation of the conditional SIRT1 transgenic mice that mimic calorie restriction induced SIRT1 overexpression.
###end title 12
###begin p 13
###xml 760 764 757 761 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STOP</sup>
###xml 876 880 873 877 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STOP</sup>
###xml 1022 1031 1019 1024 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;STOP</sup>
###xml 1052 1056 1045 1049 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STOP</sup>
###xml 1209 1218 1199 1204 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;STOP</sup>
###xml 1239 1243 1225 1229 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STOP</sup>
###xml 133 137 <span type="species:ncbi:10116">rats</span>
###xml 283 288 <span type="species:ncbi:10090">mouse</span>
###xml 524 529 <span type="species:ncbi:10090">mouse</span>
###xml 979 994 <span type="species:ncbi:10090">transgenic mice</span>
(A) Western blot analysis showing expression levels in the gut epithelium of SIRT1 in ad libitum-fed (AL) or calorie restricted (CR) rats. beta-actin served as the loading control in all lanes. (B) Schematic representation of the strategy used for the generation of the floxed SIRT1 mouse embryonic stem (MES) cells. SIRT1 was cloned downstream of a constitutive CAGGS promoter followed by a transcriptional loxP-STOP-loxP cassette. This construct was specifically targeted in the 3' UTR of the collagen A1 locus (ColA1) of mouse embryonic stem cells (MES) cells by FLP recombination. The targeted MES cells were injected into blastocysts. Red arrows indicate location of the SIRT1-Tg genotyping primers. (C) Southern blot showing the confirmation of the SIRT1STOP single integration into the Col1A locus of MES cells. (D) PCR confirming the germline transmission of the SIRT1STOP transgene to the chimaeras' offspring. (E) Western blot showing the levels of SIRT1 in the triple transgenic mice overexpressing SIRT1 (SIRT1DeltaSTOP) and controls (SIRT1STOP). beta-actin served as the loading control in all lanes. (F) Mucin stain and immunohistochemistry of SIRT1 in the small intestine of experimental (SIRT1DeltaSTOP) and controls (SIRT1STOP) animals.
###end p 13
###begin p 14
###xml 3 8 3 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">min/+</sup>
###xml 15 19 15 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STOP</sup>
###xml 85 89 85 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STOP</sup>
###xml 209 214 209 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">min/+</sup>
###xml 247 256 247 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;STOP</sup>
###xml 314 325 310 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002020.s001">Fig. S1A, B</xref>
###xml 401 410 397 402 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;STOP</sup>
###xml 498 505 490 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002020-g002">Fig. 2A</xref>
###xml 660 669 652 657 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;STOP</sup>
###xml 676 683 664 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002020-g002">Fig. 2B</xref>
###xml 863 872 851 856 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;STOP</sup>
###xml 1041 1048 1025 1032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002020-g002">Fig. 2C</xref>
###xml 1223 1228 1207 1212 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">min/+</sup>
###xml 28 32 <span type="species:ncbi:10090">mice</span>
###xml 215 219 <span type="species:ncbi:10090">mice</span>
###xml 411 426 <span type="species:ncbi:10090">transgenic mice</span>
###xml 670 674 <span type="species:ncbi:10090">mice</span>
###xml 824 829 <span type="species:ncbi:9606">human</span>
###xml 873 877 <span type="species:ncbi:10090">mice</span>
###xml 1229 1234 <span type="species:ncbi:10090">mouse</span>
APCmin/+, SIRT1STOP control mice that did not overexpress SIRT1 (referred to as SIRT1STOP) showed the typical signs of tumor morbidity at 16 weeks of age, as evidenced by overt anemia and cachexia, whereas APCmin/+ mice overexpressing SIRT1 (SIRT1DeltaSTOP) displayed no overt signs of tumor associated morbidity (Fig. S1A, B). Examination of the gut lining at four months of age showed that the SIRT1DeltaSTOP transgenic mice had significantly smaller and fewer tumors along the intestinal tract (Fig. 2A). Quantification of the tumor burden revealed a 3 to 4-fold reduction in the number and size of adenomas within the small intestine and colon of the SIRT1DeltaSTOP mice (Fig. 2B). Ki-67 is a granular component of the nucleolus that is expressed exclusively in proliferating cells and is used as a prognostic marker in human neoplasias. Adenomas of the SIRT1DeltaSTOP mice had a significant reduction in the numbers of mitoses (per high-power field) and Ki-67 staining, demonstrating that there was a decrease in adenoma proliferation (Fig. 2C). These data demonstrate that overexpression of SIRT1 in the gut at similar levels to those induced by CR is sufficient to mimic the tumor suppressive effect of CR in the APCmin/+ mouse.
###end p 14
###begin title 15
###xml 85 90 85 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">min/+</sup>
###xml 91 95 <span type="species:ncbi:10090">mice</span>
Effect of SIRT1 overexpression on intestinal tumor formation and proliferation in Apcmin/+ mice.
###end title 15
###begin p 16
###xml 114 123 114 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;STOP</sup>
###xml 144 148 140 144 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STOP</sup>
###xml 324 328 320 324 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STOP</sup>
###xml 354 363 350 355 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;STOP</sup>
###xml 519 523 511 515 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STOP</sup>
###xml 533 542 525 530 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;STOP</sup>
###xml 82 86 <span type="species:ncbi:10090">mice</span>
###xml 377 381 <span type="species:ncbi:10090">mice</span>
(A) Pictures of whole duodenal and ileal sections show gross intestinal tumors in mice overexpressing SIRT1 (SIRT1DeltaSTOP) and controls (SIRT1STOP). Solid line indicates gastro-duodenal junction. Arrows indicate adenomas. White bar denotes 1 mm scale. (B) Average number of tumors according to intestinal location in SIRT1STOP control (n = 8) and SIRT1DeltaSTOP experimental mice (n = 11). (C) Ki-67 staining of adenomas and proliferation rates. Pictures show Ki-67 immunohistochemical staining of adenomas from SIRT1STOP and SIRT1DeltaSTOP. Proliferation index is expressed as the percent of Ki-67 stained adenoma cells (averaged for at least 10 adenomas per cohort). Mitotic rate is calculated as the number of histologically identifiable mitotic figures per 10 high-power fields (400x). Values in B and C are means+/-s.d.
###end p 16
###begin p 17
###xml 343 350 340 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002020-g003">Fig. 3A</xref>
###xml 555 562 549 552 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;HY</sup>
###xml 965 974 943 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002020-g003">Fig. 3A&#8211;D</xref>
###xml 986 993 964 967 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;HY</sup>
###xml 1089 1098 1063 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002020-g003">Fig. 3B&#8211;D</xref>
###xml 577 582 <span type="species:ncbi:9606">human</span>
###xml 689 694 <span type="species:ncbi:9606">human</span>
To gain insights into the mechanisms by which SIRT1 reduces cellular proliferation, we examined the effect of SIRT1 on the growth rate of several well characterized cancer cell lines. The proliferation of LNCaP prostate cancer cells was greatly reduced by overexpression of SIRT1 and the effect was similar to suppressing beta-catenin itself (Fig. 3A). This observation suggested that SIRT1 and beta-catenin function in the same cellular context. To further explore this possibility, we overexpressed SIRT1 and a catalytically inactive SIRT1 mutant (SIRT1DeltaHY) in different human colon cancer cell lines whose growth is driven by constitutively active beta-catenin (HCT116 and DLD1). A human colon cancer cell line in which beta-catenin is inactive (RKO) served as a negative control. Increased SIRT1 expression greatly reduced proliferation in both colon cancer cell lines with constitutively active beta-catenin but not in the beta-catenin-inactive cell line (Fig. 3A-D). The SIRT1DeltaHY catalytic mutant had no significant effect on cellular proliferation in any of the cell lines (Fig. 3B-D). Thus, SIRT1 suppresses beta-catenin-driven proliferation and its catalytic activity is apparently required for this effect.
###end p 17
###begin title 18
SIRT1 inhibits beta-catenin driven cell proliferation and transcriptional activity.
###end title 18
###begin p 19
(A-D) Stable LN-CAP, DLD1, HCT116 and RKO cell lines expressing the indicated product were seeded and cell number was monitored at different time points. Western blot were performed with SIRT1, actin or beta-catenin antibodies. (E) DLD1 stable cell lines expressing Topflash-LuciferasePEST were infected with the indicated constructs. Cells were analyzed by western blot with antibodies against SIRT1 and beta-catenin. Luciferase activity was normalized for total sample protein and represents three independent experiments done in quadruplicate.
###end p 19
###begin p 20
###xml 233 237 227 231 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEST</sup>
###xml 388 395 376 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002020-g003">Fig. 3E</xref>
###xml 489 496 465 468 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;HY</sup>
###xml 529 536 501 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002020-g003">Fig. 3E</xref>
To further understand the mechanism by which SIRT1 suppresses beta-catenin-driven proliferation, we engineered the DLD1 cell line to contain a stably integrated reporter with beta-catenin response elements (Super8XTopflash-LuciferasePEST). Knockdown of beta-catenin dramatically reduced reporter activity, demonstrating the dependence of the reporter on endogenous beta-catenin activity (Fig. 3E). Overexpression of SIRT1 reduced reporter activity by approximately2-fold, whereas the SIRT1DeltaHY catalytic mutant had no effect (Fig. 3E), suggesting that the anti-proliferative effects of SIRT1 are mediated by its ability to suppress the transcriptional activity of endogenous beta-catenin and that this requires SIRT1 deacetylase activity.
###end p 20
###begin p 21
###xml 133 137 127 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Levy1">[26]</xref>
###xml 315 319 300 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Simcha1">[27]</xref>
###xml 383 390 365 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002020-g004">Fig. 4A</xref>
###xml 408 415 390 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002020-g004">Fig. 4B</xref>
###xml 494 501 473 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002020-g004">Fig. 4C</xref>
Acetylation of beta-catenin by p300/CBP potentiates its oncogenicity by increasing beta-catenin/TCF avidity at target gene promoters [26]. To test whether SIRT1 modifies beta-catenin, HEK293T cells were transfected with a mutant form of beta-catenin that constitutively localizes to the nucleus (S33Y-beta-catenin) [27]. In these cells SIRT1 co-immunoprecipitated with beta-catenin (Fig. 4A) and vice versa (Fig. 4B). An interaction between endogenous SIRT1 and beta-catenin was also apparent (Fig. 4C).
###end p 21
###begin title 22
SIRT1 represses beta-catenin transcriptional activity by directly interacting with and deacetylating beta-catenin.
###end title 22
###begin p 23
###xml 4 9 <span type="species:ncbi:9606">Human</span>
###xml 388 393 <span type="species:ncbi:9606">Human</span>
###xml 699 705 <span type="species:ncbi:9986">rabbit</span>
(A) Human 293T cells were transiently transfected with HA-S33Y-beta-catenin in combination with either FLAG-tagged SIRT1 or vector control. Aliquots of total protein were subjected to immunoprecipitation with anti-FLAG antibody (IP FLAG). Immunoprecipitated proteins were immunoblotted with anti-HA (upper panel) and anti-FLAG (lower panel). Left lanes, unprocessed extracts (input). (B) Human 293T cells were transfected as in panel A. Proteins immunoprecipitated with anti-HA antibody and immunoblotted with anti-FLAG (upper panel), and anti-HA (lower panel). Left lanes, unprocessed extracts (input). (C) Immunoprecipitation of SIRT1 from LN-CAP cell extracts using anti-SIRT1 antibody or normal rabbit IgG as a control (IgG). 10% of the immunoprecipitated protein was then blotted with anti-SIRT1 (upper panel) while the remaining 90% was blotted with anti-beta-catenin antibodies. (D) 293T cells were transfected as indicated and lysed 48 hr later. Comparable levels of beta-catenin were immunoprecipitated and blotted for acetylated-lysine residues (IP: HA IB: Ac-K; upper panel). The blot was reprobed for HA to demonstrate approximately equal levels of the HA-beta-catenin (IP: HA IB: HA; lower panel). (E-F) 293T cells were transfected as indicated together with the TOP-FLASH luciferase and PRL-TK Renilla luciferase construct. Nicotinamide (NAM) or retroviral SIRT1 shRNA (RNAi) was added as indicated. Data are normalized with respect to Renilla luciferase activity. The data are means+/-s.d. from samples performed in triplicate. (G) Indirect immunofluorescence staining of DLD-1 colon cancer cells infected with empty retrovirus or virus containing SIRT1 shRNA (RNAi) or SIRT1 cDNA (overexpression, O/E). Percent of cells with high, medium, or low levels of nuclear beta-catenin staining for untreated: 6.5, 80.6, 12.9; SIRT1 O/E: 0, 29.4, 70.5; SIRT1 RNAi: 60.0, 32.0, 0.8. Images were taken at 100x magnification.
###end p 23
###begin p 24
###xml 230 237 221 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002020-g004">Fig. 4D</xref>
###xml 317 321 308 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Simcha1">[27]</xref>
###xml 323 330 314 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002020-g004">Fig. 4E</xref>
###xml 500 510 485 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002020-g004">Fig. 4D, E</xref>
###xml 584 588 569 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Bitterman1">[28]</xref>
###xml 642 649 627 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002020-g004">Fig. 4F</xref>
To test whether SIRT1 inhibits beta-catenin by modulating its acetylation, we transfected 293T cells with S33Y-beta-catenin, the acetyltransferase p300, and increasing amounts of SIRT1. We found that p300 acetylated beta-catenin (Fig. 4D) and potentiated its transcriptional activity, as has been previously reported [27] (Fig. 4E). The addition of SIRT1, however, abolished the acetylated form of beta-catenin and significantly diminished beta-catenin activity when it was co-transfected with p300 (Fig. 4D, E). Conversely, treating cells with the SIRT1 inhibitor nicotinamide (NAM) [28] or suppressing SIRT1 with a retroviral shRNA vector (Fig. 4F) increased luciferase reporter activity. These data show that SIRT1 promotes the deacetylation of beta-catenin, thereby reducing its ability to act as a trans-activator.
###end p 24
###begin p 25
###xml 144 148 141 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Camp1">[29]</xref>
###xml 545 552 533 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002020-g004">Fig. 4G</xref>
###xml 126 133 <span type="species:ncbi:9606">patient</span>
The constitutive presence of beta-catenin in the nucleus is associated with its oncogenic function and clinically with a poor patient prognosis [29]. To test whether SIRT1 might repress beta-catenin by altering its localization, immunofluorescence was performed on cells transfected with shRNA or overexpression constructs for SIRT1. Suppression of SIRT1 in the DLD1 colon cancer cells increased the amount of nuclear beta-catenin while overexpression of SIRT1 in the same cell line led to a dramatic reduction in the nuclear beta-catenin pool (Fig. 4G).
###end p 25
###begin p 26
###xml 535 545 524 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002020-g005">Fig. 5A, B</xref>
###xml 146 151 <span type="species:ncbi:9606">human</span>
To analyze the clinical relevance of our findings, we analyzed SIRT1 and beta-catenin subcellular expression in a tissue microarray containing 81 human colon cancer samples. We found that a subset of colon cancers express SIRT1 in the nucleus (47/81 cases; 58%). When beta-catenin expression was scored in these same colon cancers, a highly significant inverse correlation between the level of SIRT1 expression and nuclear beta-catenin localization became apparent (p</=0.003, odds ratio 0.24 with 95% confidence interval 0.093-0.63) (Fig. 5A, B). Collectively, these observations suggest that modulation of beta-catenin subcellular localization is an important component of the anti-tumorigenic effects of SIRT1 with potential diagnostic and therapeutic clinical relevance.
###end p 26
###begin title 27
###xml 39 44 <span type="species:ncbi:9606">human</span>
SIRT1 expression occurs in a subset of human colon cancers and inversely correlates with the nuclear localization of beta-catenin.
###end title 27
###begin p 28
###xml 88 93 <span type="species:ncbi:9606">human</span>
###xml 274 279 <span type="species:ncbi:9606">human</span>
(A) Representative images illustrating SIRT1 and beta-catenin subcellular expression in human colon tumors. For each colon cancer case shown a text box insert indicates the detected protein (Image magnification 200x). (B) Correlation of SIRT1 and beta-catenin expression in human colon tumors. The bar graph depicts cumulative immunostaining data from a tissue microarray of 81 colon cancer cases. Nuclear expression was scored as either no expression, weak expression, or moderate/strong expression. Positivity in nucleus was defined as moderate/strong expression. All slides were interpreted by two board certified pathologist blinded from any other clinical and laboratory data.
###end p 28
###begin title 29
Discussion
###end title 29
###begin p 30
###xml 500 505 500 505 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">min/+</sup>
###xml 633 641 633 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 712 716 712 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Narala1">[30]</xref>
###xml 997 1004 997 1004 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1004 1008 1004 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Alcendor1">[31]</xref>
###xml 1139 1143 1139 1143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Mai1">[16]</xref>
###xml 1278 1285 1278 1285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 750 765 <span type="species:ncbi:10090">transgenic mice</span>
Here we describe a physiologically relevant tumor suppressive role for SIRT1 in colon cancer formation and growth. We observed that SIRT1 expression in the normal intestine occurs specifically in the enterocytes, the precursor cells that undergo neoplastic transformation in colon cancers and that SIRT1 is upregulated in rodent intestines in response to CR. We show that overexpression of SIRT1 reduces proliferation in colon cancer cell lines and that overexpressing SIRT1 in the enterocytes of APCmin/+ animals mimics the tumor suppressive effects of CR on this colon cancer model. These observations are consistent with a recent in vitro study that implicates SIRT1 as a nutrient sensitive growth suppressor [30]. While SIRT1 is expressed in our transgenic mice at higher levels than seen in the intestines of CR treated rodents (7 fold (SIRT1) versus 2 fold (CR)), this level of overexpression is, nonetheless, consistent with findings that SIRT1 can be physiologically upregulated 5-10 fold in vivo[31]. Since the tumor suppressive effects mediated by SIRT1 eclipse those seen by CR (70% reduction (SIRT1) versus 40% reduction (CR)) [16] we cannot exclude the possibility that SIRT1 also inhibits tumor growth by a CR-independent mechanism. Nevertheless, our data provide in vivo evidence that overexpression of SIRT1 at physiologically relevant levels, can suppress tumor formation and growth.
###end p 30
###begin p 31
###xml 149 154 146 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">min/+</sup>
###xml 178 183 <span type="species:ncbi:9606">human</span>
In this study, we also present evidence that SIRT1 interacts with and suppresses beta-catenin, the transcription factor that drives tumors in the APCmin/+ model and a variety of human tumors. We find that SIRT1 overexpression inhibits the growth of colon cancer cells dependent on beta-catenin activity, suppresses the localization of beta-catenin to the nucleus, and significantly attenuates its ability to activate transcription. These effects were not observed in the SIRT1-HY mutant demonstrating that SIRT1 deacetylase activity is required, and raising the possibility that SIRT1 directly targeted beta-catenin for deacetylation.
###end p 31
###begin p 32
###xml 274 278 271 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Xu1">[32]</xref>
###xml 440 447 434 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Previous studies have shown that beta-catenin is acetylated by p300/CBP and the acetylated form of the protein has increased transcriptional activity. This finding implies that the putative deacetylase that counteract p300/CBP would be useful as a cancer therapeutic target [32]. In this study, we identify SIRT1 as a deacetylase that antagonizes p300/CBP and deacetylates beta-catenin, thus slowing cellular proliferation and tumor growth in vivo.
###end p 32
###begin p 33
###xml 633 637 621 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Brack1">[23]</xref>
###xml 639 643 627 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Liu1">[24]</xref>
###xml 627 632 <span type="species:ncbi:10090">mouse</span>
Together, our data sheds light on the ability of SIRT1 to inhibit beta-catenin activity and provides mechanistic insight into the anti-tumorigenic effects of SIRT1 in a well characterized colon cancer model. Given that SIRT1 was discovered as a homolog of a longevity gene, it is interesting to note the growing evidence for a link between Wnt/beta-catenin signaling and age-associated diseases. beta-catenin has been linked to other age-associated malignancies such as melanoma, multiple myeloma, and prostate cancer. There is also the recent discovery that upregulation of Wnt/beta-catenin signaling accelerates aging in the mouse [23], [24]. Thus, it will be worth investigating whether SIRT1 can provide protection against other age-associated diseases on account of its ability to suppress Wnt/beta-catenin signaling.
###end p 33
###begin p 34
###xml 32 37 <span type="species:ncbi:10090">mouse</span>
In summary, using biochemistry, mouse genetics, and clinical tumor specimens we have found that SIRT1, a diet-responsive gene, is a regulator of beta-catenin and has a tumor suppressive function. We conclude that mammalian longevity genes with anti-apoptotic functions, surprisingly do not necessarily lead to increased tumorigenesis. In fact, we find the opposite is likely the case for SIRT1. These studies begin to answer an important biological question regarding the function of a key longevity gene in cancer development and growth and suggest a previously unidentified therapeutic potential for SIRT1 activators in cancer.
###end p 34
###begin title 35
Materials and Methods
###end title 35
###begin title 36
Rodents
###end title 36
###begin p 37
###xml 68 72 68 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">loxP</italic>
###xml 354 358 354 358 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STOP</sup>
###xml 746 751 734 739 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">min/+</sup>
###xml 872 876 860 864 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STOP</sup>
###xml 958 963 946 951 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">min/+</sup>
###xml 981 985 969 973 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STOP</sup>
###xml 990 995 978 983 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">min/+</sup>
###xml 1099 1108 1087 1092 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;STOP</sup>
###xml 1122 1127 1106 1111 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">min/+</sup>
###xml 205 210 <span type="species:ncbi:10090">mouse</span>
###xml 658 662 <span type="species:ncbi:10090">mice</span>
###xml 767 782 <span type="species:ncbi:10090">transgenic mice</span>
###xml 931 935 <span type="species:ncbi:10090">mice</span>
###xml 1054 1069 <span type="species:ncbi:10090">transgenic mice</span>
A Cre-inducible SIRT1 expression construct was generated in which a loxP flanked transcriptional STOP element was inserted between a CAGGS promoter and the SIRT1 cDNA. This construct was targeted into the mouse Collagen A1 locus using flp recombinase-mediated genomic integration as described previously (1). MES cells carrying a single copy of the SIRT1STOP construct were identified by resistance to the antibiotic marker hygromycin and Southern blotting. PCR primers and construct maps are available upon request. Two clones were injected into blastocysts and both generated pups, approximately90% of which displayed germ-line transmission. Tumor bearing mice that were analyzed had been backcrossed at least four generations into C57/BL6. APCmin/+ and Villin-Cre transgenic mice strains were obtained in the C57/BL6 background from Jackson Labs (Bar Harbor, ME). SirT1STOP animals were backcrossed two generations into C57BL/6 mice before crossing to APCmin/+ to generate SirT1STOP; APCmin/+ double transgenics. These animals were bred to Villin-Cre transgenic mice to generate a cohort of SirT1DeltaSTOP; Vil-Cre; APCmin/+ animals. Animals were maintained at Harvard Medical School and experiments were approved by the Animal Care Committee of Harvard Medical School.
###end p 37
###begin p 38
###xml 24 28 <span type="species:ncbi:10116">rats</span>
###xml 147 151 <span type="species:ncbi:10116">rats</span>
###xml 470 474 <span type="species:ncbi:10116">rats</span>
Male Fischer-344 (F344) rats were bred and reared in a vivarium at the Gerontology Research Center (GRC, Baltimore, MD). From weaning (2 Wks), the rats were housed individually in standard plastic cages with beta chip wood bedding. Control animals were fed a NIH-31 standard diet ad libitum (AL). At 1 month of age the calorie restricted (CR) animals were provided a vitamin and mineral fortified version of the same diet at a level of 40% less food (by weight) than AL rats consumed during the previous week. Filtered and acidified water was available ad libitum for both groups. The vivarium was maintained at a temperature of 25degreesC with relative humidity at 50% on a 12/12-hour light/dark cycle (lights on at 6:00 a.m.) All animals were 6 months of age and sacrificed between 9:00 and 11:00 a.m. The intestine was quickly removed and thoroughly flushed with ice cold PBS and placed into liquid nitrogen then stored at -80degreesC until processed for Western blotting using standard procedures.
###end p 38
###begin title 39
Animal Pathology, Histopathology and Immunohistochemical analysis
###end title 39
###begin p 40
###xml 670 675 <span type="species:ncbi:10090">mouse</span>
###xml 800 806 <span type="species:ncbi:9986">rabbit</span>
###xml 851 854 <span type="species:ncbi:9685">cat</span>
###xml 865 871 <span type="species:ncbi:9986">rabbit</span>
###xml 905 910 <span type="species:ncbi:10090">mouse</span>
###xml 966 969 <span type="species:ncbi:10116">rat</span>
###xml 975 980 <span type="species:ncbi:10090">mouse</span>
For gross tumor analysis, the entire intestine was excised immediately after sacrifice, opened lengthwise and washed with cold phosphate-buffered saline (PBS) while pinned down a solid support. Adenomas larger than 0.5mm from the proximal (10 cm distal to the pylorus), distal (10 cm proximal to the cecum), and middle (approximately50% of total intestinal length) small intestine as well as the colon were scored. Intestines were prepared using the Swiss roll method by rotating them around a glass pipette tip. Tissues were fixed and embedded in paraffin using standard histology protocol. Precise tumor size was scored microscopically on hematoxylin/eosin stained of mouse intestines using a microscope with an eyepiece micrometer. Immunohistochemical analysis of rodent tissue was performed with rabbit anti-SIRT1 antibody (Upstate Biotechnology, cat #07-131), rabbit anti-beta catenin (abcam #2982), mouse anti-beta-catenin (Clone 14, BD transduction labs) and rat anti-mouse Ki-67 (Dako).
###end p 40
###begin title 41
Immunohistochemical and Statistical Analyses
###end title 41
###begin p 42
###xml 67 71 67 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002020-Ogino1">[33]</xref>
###xml 402 403 399 400 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 404 405 401 402 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 478 482 <span type="species:ncbi:9925">goat</span>
Tissue microarrays (TMAs) were constructed as previously described [33] using the Automated Arrayer (Beecher Instruments, Sun Prairie, WI USA). For beta-catenin and SIRT1 immunohistochemistry, antigen retrieval was performed; deparaffinized tissue sections were treated by a microwave for 15 min in citrate buffer (BioGenex, San Ramon, CA) in a pressure cooker. Tissue sections were incubated with 3% H2O2 (15 min) to block endogenous peroxidase, then incubated with 10% normal goat serum (Vector Laboratories, Burlingame, CA) in PBS (10 min), followed by 10 min incubation in serum free protein block (DAKO, Carpinteria, CA). Primary antibody against beta-catenin (clone 14, BD Transduction Laboratories, Franklin Lakes, NJ) (dilution 1:400) or SIRT1 (#1104; Epitomics) (dilution 1:100) was applied for 1 hour at room temperature. Secondary antibody (BioGenex) (20 min), and then streptavidin peroxidase conjugate (BioGenex) were applied (20 min). Sections were visualized by diaminobenzidine (DAB) (2 min) and methyl-green counterstain. Nuclear expression was recorded as either no expression, weak expression, or moderate/strong expression. Positivity in nucleus was defined as moderate/strong expression. All beta-catenin-stained TMA slides were interpreted by a pathologist (S.O.) blinded from any other clinical and laboratory data. All SIRT1-stained TMA slides were interpreted by a pathologist (R.F.) blinded from any other clinical and laboratory data. For statistical analysis, chi-square test was performed for categorical data using the SAS software program (Version 9.1, SAS Institute, Cary, NC). The p-value was two-sided, and statistical significance was set at p </= 0.05.
###end p 42
###begin title 43
Plasmids
###end title 43
###begin p 44
###xml 61 68 61 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;HY</sup>
pcDNA3-FLAG-SIRT1, pBABE-Puro-hSir2 (SIRT1), pBABE-Puro-SIRT1DeltaHY, pcDNA-HA-S33Y-beta-catenin and pBABE-Puro-S33Y- beta-catenin have been described before. SIRT1 RNAi plasmids were constructed by cloning the sequences into the pSUPER.retro plasmid (oligoEngine, Seattle, WA). One TOPFLASH plasmid was purchased from Upstate Biotechnology (Lake Placid, NY) while the second was generated by cloning the tandem TCF binding sites and TA-promoter from SUPER8xTOPFLASH (kind gift of Randall Moon) into the Luciferase-PEST plasmid pGL4.15 (Promega, Madison, WI).
###end p 44
###begin title 45
Cell Transfections, Infections and Immunocytochemistry
###end title 45
###begin p 46
###xml 202 203 202 203 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
293T, LN-CAP, DLD1, HCT116 and RKO cells were maintained in the recommended tissue culture media (American Type Culture Collection (ATCC), Manassas, VA) and grown in a humidified incubator containing CO2 (5% v/v) at 37degreesC. For over-expression experiments, plasmids were transfected by the Fugene 6 method (Roche). For stable cell line generation, DLD1 cells were selected in hygromycin for two weeks and single colonies were picked and expanded. For retroviral production, 293T cells were transfected with the overexpression or RNAi plasmids simultaneously with packaging plasmids gag-pol and VSV-G or pCL-ampho. The media containing the progeny virus released for the 293T cells was collected and used to infect the cells for 3-6 hours in the presence of 8 microg/ml polybrene (Sigma Aldrich, St. Louis, MO). The medium was changed and cells were incubated for additional 24-48 hour incubation. They were selected with puromycin (Sigma Aldrich) for 24-48 hours and then trypsinized and seeded for experiments.
###end p 46
###begin p 47
###xml 457 461 <span type="species:ncbi:9925">goat</span>
###xml 467 473 <span type="species:ncbi:9986">rabbit</span>
###xml 498 502 <span type="species:ncbi:9925">goat</span>
###xml 508 513 <span type="species:ncbi:10090">mouse</span>
For immunocytochemistry, cells were plated on 8 mm six well Teflon printed slides (Electron Microscopy Sciences). Twenty four hours after plating, cells were fixed by incubation with 4% Paraformaldehyde for 30 minutes. Fixed cells were then incubated with primary antibodies to SIRT1 (#1104; Epitomics (dilution 1:100) and active beta-catenin (05-665; Chemicon) (dilution 1:100) for 2 hours followed by incubation with secondary antibodies (Alexa Fluor 488 goat anti-rabbit IgG and Alexa Fluor 568 goat anti-mouse IgG; Molecular Probes) (dilution 1:400). Cells were incubated with 10 microg/ml Hoechst, washed and mounted with a coverslip. At least 20 cells were scored per experiment and image capture was performed using an Olympus BX50 microscope.
###end p 47
###begin title 48
Protein Extraction and Immunoprecipitation
###end title 48
###begin p 49
###xml 617 618 613 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
Cell extracts analyzed directly by Western blotting were prepared by cell lysis in 1x SDS loading buffer followed by boiling and Western analysis. Cell extracts for immunoprecipitation were prepared by resuspending phosphate-buffered saline-washed cell pellets in 1 ml of Nonidet P-40 (NP-40) extraction buffer (50 mM Tris-HCl [pH 8.0], 150 mM NaCl, and 1% Nonidet P-40) supplemented with EDTA-free protease inhibitor cocktail tablets (Roche) with 10 mM Nicotinamide (NAA) and 5 microM Trichostatin-A (TSA). Following incubation on ice for 30 minutes, non-extractable material was removed by centrifugation at 17,000 g for 10 min at 4degreesC, and the cleared supernatants were employed for immunoprecipitation. Lysates were immunoprecipitated (2 hr), washed 4 times with NP-40 buffer and were processed by Western blotting.
###end p 49
###begin title 50
Proliferation Assays
###end title 50
###begin p 51
DLD1, HCT116 and RKO cell lines infected with the appropriate construct were seeded in 24 well plates at a density of 10,000 cells. Cells were trypsinized and analyzed by Coulter counting at given time points.
###end p 51
###begin title 52
Luciferase Assay
###end title 52
###begin p 53
Luciferase assay was done as instructed by the dual luciferase reporter assay system or firefly luciferase assay system (Promega, Madison, WI).
###end p 53
###begin title 54
Western Blotting and RNA Analysis
###end title 54
###begin p 55
###xml 312 318 <span type="species:ncbi:9986">rabbit</span>
###xml 372 375 <span type="species:ncbi:9685">cat</span>
###xml 389 395 <span type="species:ncbi:9986">rabbit</span>
###xml 437 440 <span type="species:ncbi:9685">cat</span>
For expression studies, animal intestines were flushed with cold PBS and either homogenized whole or scraped to enrich for enterocytes. Protein extracts were prepared by dounce homogenization in standard lysis buffer, subjected to SDS-PAGE and transferred onto PVDF membranes. Membranes were immunoblotted using rabbit polyclonal antibody to SIRT1 (Upstate Biotechnology, cat #07-131) and rabbit polyclonal antibody to beta-actin (Abcam cat #8226). Densitometric analysis was performed on scanned images of blots using ImageJ software (NIH Image analysis website )
###end p 55
###begin title 56
Supporting Information
###end title 56
###begin p 57
###xml 3 8 3 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">min/+</sup>
###xml 79 84 79 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">min/+</sup>
###xml 117 126 117 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;STOP</sup>
###xml 212 216 208 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STOP</sup>
###xml 9 13 <span type="species:ncbi:10090">mice</span>
###xml 85 89 <span type="species:ncbi:10090">mice</span>
###xml 302 306 <span type="species:ncbi:10090">mice</span>
APCmin/+ mice overexpressing SIRT1 in gut show less signs of morbidity. (A) APCmin/+ mice overexpressing SIRT1 (SIRT1DeltaSTOP) show less anemia than their non SIRT1 overexpressing age matched counterparts (SIRT1STOP) as reflected by the color of their paws. (B) Graph depicting average body weight of mice at time of sacrifice (n = at least 4 per group). Error bars represent average+/-S.D.
###end p 57
###begin p 58
(2.31 MB TIF)
###end p 58
###begin p 59
Click here for additional data file.
###end p 59
###begin p 60
We thank Moshe Oren for kindly providing the S33Y-beta-catenin plasmid.
###end p 60
###begin title 61
References
###end title 61
###begin article-title 62
###xml 23 27 <span type="species:ncbi:10090">mice</span>
Dietary restriction in mice beginning at 1 year of age: effect on life-span and spontaneous cancer incidence.
###end article-title 62
###begin article-title 63
Toward a unified theory of caloric restriction and longevity regulation.
###end article-title 63
###begin article-title 64
Calorie restriction-the SIR2 connection.
###end article-title 64
###begin article-title 65
Sirtuin functions in health and disease.
###end article-title 65
###begin article-title 66
SIRT1: Tumor promoter or tumor suppressor?
###end article-title 66
###begin article-title 67
Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses.
###end article-title 67
###begin article-title 68
Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase.
###end article-title 68
###begin article-title 69
SIRT1 interacts with p73 and suppresses p73-dependent transcriptional activity.
###end article-title 69
###begin article-title 70
###xml 42 47 <span type="species:ncbi:9606">human</span>
Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival.
###end article-title 70
###begin article-title 71
Mammalian SIRT1 represses forkhead transcription factors.
###end article-title 71
###begin article-title 72
Inhibition of SIRT1 Reactivates Silenced Cancer Genes without Loss of Promoter DNA Hypermethylation.
###end article-title 72
###begin article-title 73
Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase.
###end article-title 73
###begin article-title 74
Hormonal Control of Androgen Receptor Function through SIRT1.
###end article-title 74
###begin article-title 75
Mammalian SIRT1 limits replicative life span in response to chronic genotoxic stress.
###end article-title 75
###begin article-title 76
Sirtuins: critical regulators at the crossroads between cancer and aging.
###end article-title 76
###begin article-title 77
###xml 99 103 <span type="species:ncbi:10090">mice</span>
Calorie restriction and diet composition modulate spontaneous intestinal tumorigenesis in Apc(Min) mice through different mechanisms.
###end article-title 77
###begin article-title 78
###xml 58 64 <span type="species:ncbi:10090">murine</span>
Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene.
###end article-title 78
###begin article-title 79
Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein.
###end article-title 79
###begin article-title 80
Association of the APC gene product with beta-catenin.
###end article-title 80
###begin article-title 81
The Wnt signaling pathway in development and disease.
###end article-title 81
###begin article-title 82
Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma.
###end article-title 82
###begin article-title 83
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC.
###end article-title 83
###begin article-title 84
Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis.
###end article-title 84
###begin article-title 85
Augmented Wnt signaling in a mammalian model of accelerated aging.
###end article-title 85
###begin article-title 86
Tissue-specific and inducible Cre-mediated recombination in the gut epithelium.
###end article-title 86
###begin article-title 87
Acetylation of beta-catenin by p300 regulates beta-catenin-Tcf4 interaction.
###end article-title 87
###begin article-title 88
Differential nuclear translocation and transactivation potential of beta-catenin and plakoglobin.
###end article-title 88
###begin article-title 89
###xml 96 101 <span type="species:ncbi:4932">yeast</span>
###xml 111 116 <span type="species:ncbi:9606">human</span>
Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1.
###end article-title 89
###begin article-title 90
Automated subcellular localization and quantification of protein expression in tissue microarrays.
###end article-title 90
###begin article-title 91
SIRT1 Acts as a Nutrient-sensitive Growth Suppressor and its Loss is Associated with Increased AMPK and Telomerase Activity.
###end article-title 91
###begin article-title 92
Sirt1 regulates aging and resistance to oxidative stress in the heart.
###end article-title 92
###begin article-title 93
Mechanistic insights from structural studies of beta-catenin and its binding partners.
###end article-title 93
###begin article-title 94
Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer.
###end article-title 94
###begin p 95
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: Leonard Guarente and David Sinclair are consultants to Sirtris Pharmaceuticals. William Hahn is a consultant to Novartis Pharmaceuticals.
###end p 95
###begin p 96
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: RF was supported by the NIH T32 Grant. GB by an Estee Lauder postdoctoral fellowship. PO by a National Space Biomedical Research Institute Grant. DAS, SO, CSF and LG by grants from NIH; RD in part by the Intramural Research Program of the NIH/NIA. DS is also supported by a gift from the Paul F. Glenn Foundation.
###end p 96

